Loading clinical trials...
Loading clinical trials...
A Multicentre, Randomized, Open-label, Phase III Study Comparing the Efficacy of Oral Glutamine and Calcium-magnesium With Calcium-magnesium Alone in the Prevention of Oxaliplatin-induced Neurotoxicity in Patients With Colorectal Cancer Treated With Oxaliplatin in Adjuvant or 1st Line Metastatic Settings.
Conditions
Interventions
Glutamine
Calcium and Magnesium
Locations
14
Canada
Investigational Site Number 0001
Greenfield Park, Canada
Investigational Site Number 124-005
Laval, Canada
Investigational Site Number 124-007
London, Canada
Investigational Site Number 124-014
Moncton, Canada
Investigational Site Number 124-006
Montreal, Canada
Investigational Site Number 124-004
Montreal, Canada
Start Date
February 1, 2010
Primary Completion Date
March 1, 2013
Completion Date
March 1, 2013
Last Updated
June 21, 2013
NCT06662786
NCT06663319
NCT05239741
NCT05770102
NCT04812912
NCT06778382
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions